Finding non-hallucinogenic drugs to help treat addiction
High-throughput Identification of Non-hallucinogenic Psychoplastogens for Treating Addiction
This study is looking for new, safe treatments for addiction that can help repair brain cells in an important area of the brain, which could make it easier for people to overcome their cravings for drugs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11039940 on NIH RePORTER |
What this research studies
This research investigates the potential of non-hallucinogenic psychoplastogens to treat addiction by restoring the structure and function of neurons in the prefrontal cortex, which is crucial for controlling drug-seeking behavior. The approach involves identifying small molecules that can activate brain-derived neurotrophic factor (BDNF) signaling, which may help reverse the neural atrophy associated with substance use disorders. By using advanced screening techniques, the researchers aim to discover compounds that provide therapeutic benefits without the adverse effects of hallucinations. This could lead to new treatment options for individuals struggling with addiction.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from substance use disorders who are seeking alternative treatment options.
Not a fit: Patients who do not have substance use disorders or those who are not open to pharmacological interventions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new, effective treatments for addiction that do not cause hallucinations.
How similar studies have performed: Other research has shown promise in using psychoplastogens for therapeutic purposes, suggesting that this approach may lead to significant advancements in addiction treatment.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Olson, David E — University of California at Davis
- Study coordinator: Olson, David E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.